Results 181 to 190 of about 36,891 (208)
Some of the next articles are maybe not open access.
Hämostaseologie, 2012
SummaryApixaban is a potent reversible inhibitor of the activated human coagulation factor X. This new oral anticoagulant has favourable pharmacokinetic and pharmocodynamic properties which include a concentration-dependent anticoagulant effect, good oral bioavailability, balanced elimination and excretion, infrequent drug or food interactions, and the
S, Konstantinides, T, Münzel
openaire +2 more sources
SummaryApixaban is a potent reversible inhibitor of the activated human coagulation factor X. This new oral anticoagulant has favourable pharmacokinetic and pharmocodynamic properties which include a concentration-dependent anticoagulant effect, good oral bioavailability, balanced elimination and excretion, infrequent drug or food interactions, and the
S, Konstantinides, T, Münzel
openaire +2 more sources
Drugs, 2011
Apixaban (Eliquis™), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders. Apixaban has been approved in the EU for the prevention of venous thromboembolism (VTE) after hip or knee replacement.
Julia, Watson +2 more
openaire +2 more sources
Apixaban (Eliquis™), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders. Apixaban has been approved in the EU for the prevention of venous thromboembolism (VTE) after hip or knee replacement.
Julia, Watson +2 more
openaire +2 more sources
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
New England Journal of Medicine, 2020Giancarlo Agnelli +2 more
exaly